Dr.Banu Arun is Professor in Department of Breast Medical Oncology, Co-Medical Director of the Clinical Cancer Genetics Program and Section Chief Breast Genetics, Prevention and Screening, and Executive Director of Cancer Genetics MD Anderson Cancer Networks at the University of Texas MD Anderson Cancer Center. Her research focuses on identifying risk biomarkers for breast cancer and prevention, and characterizing risk factors in a cohort of high-risk women with hereditary gene mutations (BRCA and others) as well as assessing breast cancer biology in these patients. She has served as the Principal Investigator on several clinical trials evaluating agents such as letrozole, imatinib, gemcitabine, R115777 and PARP inhibitors for metastatic breast cancer (including BRCA positive) and celecoxib, atorvastatin, dasatinib and Tamoxifen gel in short-term breast cancer prevention trials. Her research also include community outreach and education, as well as cascade genetic testing of family members.

Given her national and international expertise she has served in several committees, including The American Society of Clinical Oncology (ASCO) Prevention committee, ASCO Genetics Guideline Committee and currently serves as the Co-Chair for the Southwest Oncology Group (SWOG) Prevention and Epidemiology Committee, member of the NCCN Breast Cancer Risk Reduction Guideline Committee as well the Hereditary Breast, Ovarian, Prostate and Pancreas cancer Guideline Committee, member of the National Cancer Institute (NCI) Cancer Prevention Steering Committee, member of the ACS Cancer Risk360 Advisory Committee and member of the ESMO (European Society of Medical Oncology) Early Detection and Prevent Task Force,. She served as grant reviewer for Susan Komen and NCI P01 and reviewed for journals including  JCO, Cancer, BMJ, Cancer Prevention and Epidemiology, amongst others. She has more than 250 peer reviewed publications and received research grants from the NCI, Susan Komen Foundation, Department of Defense and CPRIT.
She was featured in Forbes (December 2017) as one of the top 30 Breast Medical Oncologists in the United States. She has also received FASCO award recognition in 2020 from the American Society of Clinical Oncology and is the recipient of the ASCO–American Cancer Society Life-Time Achievement Award 2021.